Valley National Advisers Inc. Sells 3,028 Shares of Thermo Fisher Scientific Inc. $TMO

Valley National Advisers Inc. lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 92.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 254 shares of the medical research company’s stock after selling 3,028 shares during the quarter. Valley National Advisers Inc.’s holdings in Thermo Fisher Scientific were worth $122,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. Mayflower Financial Advisors LLC increased its holdings in Thermo Fisher Scientific by 0.9% in the third quarter. Mayflower Financial Advisors LLC now owns 2,838 shares of the medical research company’s stock valued at $1,376,000 after purchasing an additional 25 shares during the period. NovaPoint Capital LLC bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $1,101,000. Valicenti Advisory Services Inc. raised its position in shares of Thermo Fisher Scientific by 0.3% during the third quarter. Valicenti Advisory Services Inc. now owns 10,280 shares of the medical research company’s stock worth $4,986,000 after acquiring an additional 35 shares during the last quarter. FSM Wealth Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 45.9% in the third quarter. FSM Wealth Advisors LLC now owns 731 shares of the medical research company’s stock worth $354,000 after acquiring an additional 230 shares during the period. Finally, Apella Capital LLC increased its position in Thermo Fisher Scientific by 13.4% during the 3rd quarter. Apella Capital LLC now owns 726 shares of the medical research company’s stock valued at $390,000 after purchasing an additional 86 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Michael D. Shafer sold 10,725 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total value of $6,435,000.00. Following the sale, the executive vice president owned 18,731 shares in the company, valued at $11,238,600. This represents a 36.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Lisa P. Britt sold 1,058 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total value of $622,379.08. Following the transaction, the vice president owned 13,087 shares of the company’s stock, valued at $7,698,558.62. This trade represents a 7.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 149,271 shares of company stock worth $86,507,282 in the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. The Goldman Sachs Group began coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, December 9th. They issued a “buy” rating and a $685.00 price target on the stock. Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, October 8th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. JPMorgan Chase & Co. boosted their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Finally, Barclays raised their target price on Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $616.60.

Thermo Fisher Scientific Price Performance

TMO stock opened at $580.65 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The company’s 50-day moving average is $573.94 and its 200-day moving average is $504.12. The stock has a market capitalization of $218.16 billion, a PE ratio of 33.54, a price-to-earnings-growth ratio of 4.12 and a beta of 0.90. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. During the same period in the prior year, the business earned $5.28 EPS. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has initiated a stock buyback program on Thursday, November 6th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.